1. Home
  2. YJ vs KALA Comparison

YJ vs KALA Comparison

Compare YJ & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yunji Inc. American Depository Shares

YJ

Yunji Inc. American Depository Shares

N/A

Current Price

$1.49

Market Cap

7.4M

ML Signal

N/A

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.65

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YJ
KALA
Founded
2015
2009
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4M
6.7M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
YJ
KALA
Price
$1.49
$0.65
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$31.50
AVG Volume (30 Days)
4.3K
22.1M
Earning Date
03-20-2026
11-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$47,760,127.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.37
$0.51
52 Week High
$2.67
$20.60

Technical Indicators

Market Signals
Indicator
YJ
KALA
Relative Strength Index (RSI) 38.61 40.02
Support Level $1.41 $0.57
Resistance Level $1.69 $0.72
Average True Range (ATR) 0.09 0.09
MACD 0.01 0.05
Stochastic Oscillator 6.67 39.53

Price Performance

Historical Comparison
YJ
KALA

About YJ Yunji Inc. American Depository Shares

Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: